Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sangamo Therapeutics stock | 11.37

Own Sangamo Therapeutics stock in just a few minutes.

Posted

Fact checked

Sangamo Therapeutics, Inc is a biotechnology business based in the US. Sangamo Therapeutics shares (SGMO) are listed on the NASDAQ and all prices are listed in US Dollars. Sangamo Therapeutics employs 354 staff and has a trailing 12-month revenue of around USD$147.2 million.

How to buy shares in Sangamo Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Sangamo Therapeutics. Find the stock by name or ticker symbol: SGMO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sangamo Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$11.37, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sangamo Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Sangamo Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Sangamo Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Sangamo Therapeutics's share price has had significant positive movement.

Its last market close was USD$11.37, which is 34.56% up on its pre-crash value of USD$7.44 and 136.38% up on the lowest point reached during the March crash when the shares fell as low as USD$4.81.

If you had bought USD$1,000 worth of Sangamo Therapeutics shares at the start of February 2020, those shares would have been worth USD$802.76 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,557.58.

Sangamo Therapeutics share price

Use our graph to track the performance of SGMO stocks over time.

Sangamo Therapeutics shares at a glance

Information last updated 2020-11-24.
Latest market close USD$11.37
52-week range USD$4.81 - USD$13.2
50-day moving average USD$10.8617
200-day moving average USD$10.6924
Wall St. target price USD$20.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.988

Buy Sangamo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sangamo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sangamo Therapeutics price performance over time

Historical closes compared with the close of $11.37 from 2020-11-16

1 week (2020-11-20) N/A
1 month (2020-10-30) 9.96%
3 months (2020-08-28) N/A
6 months (2020-05-28) N/A
1 year (2019-11-27) N/A
2 years (2018-11-27) N/A
3 years (2017-11-27) N/A
5 years (2015-11-27) N/A

Sangamo Therapeutics financials

Revenue TTM USD$147.2 million
Gross profit TTM USD$-43,494,000
Return on assets TTM -6.6%
Return on equity TTM -16.16%
Profit margin -51.51%
Book value $3.692
Market capitalisation USD$1.4 billion

TTM: trailing 12 months

Shorting Sangamo Therapeutics shares

There are currently 20.4 million Sangamo Therapeutics shares held short by investors – that's known as Sangamo Therapeutics's "short interest". This figure is 3.4% down from 21.1 million last month.

There are a few different ways that this level of interest in shorting Sangamo Therapeutics shares can be evaluated.

Sangamo Therapeutics's "short interest ratio" (SIR)

Sangamo Therapeutics's "short interest ratio" (SIR) is the quantity of Sangamo Therapeutics shares currently shorted divided by the average quantity of Sangamo Therapeutics shares traded daily (recently around 1.2 million). Sangamo Therapeutics's SIR currently stands at 16.87. In other words for every 100,000 Sangamo Therapeutics shares traded daily on the market, roughly 16870 shares are currently held short.

However Sangamo Therapeutics's short interest can also be evaluated against the total number of Sangamo Therapeutics shares, or, against the total number of tradable Sangamo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sangamo Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Sangamo Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.1441% of the tradable shares (for every 100,000 tradable Sangamo Therapeutics shares, roughly 144 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sangamo Therapeutics.

Find out more about how you can short Sangamo Therapeutics stock.

Sangamo Therapeutics share dividends

We're not expecting Sangamo Therapeutics to pay a dividend over the next 12 months.

Sangamo Therapeutics share price volatility

Over the last 12 months, Sangamo Therapeutics's shares have ranged in value from as little as $4.81 up to $13.2. A popular way to gauge a stock's volatility is its "beta".

SGMO.US volatility(beta: 2.04)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sangamo Therapeutics's is 2.0355. This would suggest that Sangamo Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sangamo Therapeutics overview

Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site